奈达铂同步放化疗治疗无手术指征食管癌的增敏疗效及临床观察  

Study on sensitization effect and clinical observation of concurrent nedaplatin combined with radiotherapy for patients with esophageal cancer of no surgical indications

作　　者：黄培 孙清 赵帆 过雪丹 Huang Pei;Sun Qing;Zhao Fan;Guo Xuedan(Department of Oncology,Wuxi No.2 Hospital Affiliated to Nanjing Medical University,Jiangsu Wuxi 214002,China.)

机构地区：[1]南京医科大学附属无锡第二医院肿瘤科

出　　处：《现代肿瘤医学》2020年第4期595-598,共4页Journal of Modern Oncology

基　　金：江苏省卫生计生委人事人才课题(编号:R2017005)

摘　　要：目的:研究奈达铂同步放化疗治疗无手术指征食管癌的增敏疗效及临床观察。方法:收治2011年1月至2013年12月中晚期食管癌患者47例,经病理证实且失去手术指征的食管癌患者,随机分成两组,其中实验组23例,予奈达铂同步放化疗,对照组24例,予单纯放疗。结果:实验组有效率为69.57%,对照组为54.17%,两组差异无统计学意义(P>0.05);放射性肺炎、放射性食管炎、血小板下降、血红蛋白下降两组差异无统计学意义(P>0.05);胃肠道反应、白细胞下降两组差异有统计学意义(P<0.05),实验组明显高于对照组;实验组1、2、3年生存率分别为82.6%、65.2%、21.7%,对照组分别为75.0%、33.3%、12.5%,1、3年生存率差异无统计学意义(P>0.05),2年生存率差异有统计学意义(P<0.05),两组生存率随时间递增而递减,实验组生存率高于对照组。结论:奈达铂同步放化疗治疗无手术指征食管癌可以提高疗效,可能延长生存期,但毒副反应相对明显。To investigate the sensitization effect and clinical observation of concurrent nedaplatin combined with radiotherapy for patients with esophageal cancer of no surgical indications.Methods:From January 2011 to December 2013,47 cases of patients with esophageal cancer were randomly divided into 2 groups,including 23 cases in the treatment group,which treated with radiotherapy and nedaplatin concurrently,and 24 cases in the control group treated with radiotherapy only.Results:The effective rate was 69.57%in the treatment group and 54.17%in control group.There was no significant difference between the two groups in radiation pneumonia,radiation esophagitis,thrombocytopenia and hemoglobin decline.The incidence of gastrointestinal reaction and leukocyte decline in the treatment group were significantly higher than those in the control group(P<0.05).The 1-year,2-year and 3-year survival rates in the treatment group were 82.6%,65.2%and 21.7%,respectively,another were 75.0%,33.3%,12.5%.There was no statistically significant difference in 1-and 3-year survival rate(P>0.05),while significant difference in 2-year survival rate(P<0.05).The survival rate of the treatment group was higher than that of the control group.Conclusion:Nedaplatin combined with concurrent chemoradiotherapy in patients with esophageal cancer of no surgical indications can improve the curative effect,but may have obvious toxic and side effects.

关 键 词：奈达铂 同步放化疗 食管癌 无手术指征 

分 类 号：R735.1[医药卫生—肿瘤]